Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Ka Inhibitor Program [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
WILMINGTON, Del., March 20, 2026 BUSINESS WIRE )--Synnovation Therapeutics, LLC ("Synnovation"), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, Inc. ("Pikavation") and its portfolio of PI3Ka inhibitor programs, including SNV4818. Pikavation is a wholly-owned subsidiary of Synnovation. SNV4818 is a potentially best-in-class pan-mutant selective PI3Ka inhibitor currently in Phase 1/2 clinical trials for the treatment of HR+/HER2- metastatic breast cancer and other solid tumors. "We believe Novartis's global capabilities and commitment to patients with cancer will accelerate the development of SNV4818 for patients with PI3Ka mutation–driven solid tumors beyond what Synnovation could achieve alone," said Wenqing Yao, Ph.D, Chief Executive Officer of Synnovation. "This acquisition reflects the strength of the Synnov
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis Strikes $3B Oncology Deal for Breast Cancer Asset [Yahoo! Finance]Yahoo! Finance
- Novartis to acquire SNV4818 from Synnovation [Yahoo! Finance]Yahoo! Finance
- Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance]Yahoo! Finance
- Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website